Pseudomonas aeruginosa serotypes and resistance to antibiotics from wound swabs;Serotipovi i rezistencija na antibiotike Pseudomonas aeruginosa iz briseva rana

Vojnosanitetski Pregled

Volumn 72, Issue 11, 2015, Pages 996-1003

  Nedeljković, Nataša Stanković ^a   Tiodorović, Branislav ^b   Kocić, Branislava ^b   Ćirić, Vojislav ^c   Milojković, Marko ^d   Waisi, Hadi ^e  

^a Health Center Aleksinac   (Serbia)

^b UNIVERSITY OF NI   (Serbia)

^c University Clinical Center   (Serbia)

^d School of Agriculture umatovac   (Serbia)

^e Institute for Water Resources Jaroslav arni   (Serbia)

Author keywords

Anti bacterial agents; Drug resistance; Pseudomonas aeruginosa; Serotyping; Wounds infection

Indexed keywords

AMIKACIN; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; GENTAMICIN; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE; NETILMICIN; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT;

ADULT; AGED; AGGLUTINATION TEST; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM IDENTIFICATION; BURN; COMPARATIVE STUDY; FEMALE; HUMAN; LEG ULCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; PSEUDOMONAS AERUGINOSA; SEROTYPING; SURGICAL WOUND; WOUND INFECTION; CLASSIFICATION; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

AGED; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; SEROTYPING; WOUND INFECTION;

EID: 84946414477     PISSN: 00428450     EISSN: 24060720     Source Type: Journal    
DOI: 10.2298/VSP131224108S     Document Type: Article

References (46)

1. Severino P, Magalhães VD. The role of integrons in the dissemination of antibiotic resistance among clinical isolates of Pseudomonas aeruginosa from an intensive care unit in Brazil. Res Microbiol 2002; 153(4): 221-6.
2. Loughlin MF, Jones MV, Lambert PA. Pseudomonas aeruginosa cells adapted to benzalkonium chloride show resistance to other membrane-active agents but not to clinically relevant antibiotics. J Antimicrob Chemother 2002; 49(4): 631-9.
3. Li L, Ledizet M, Kar K, Koski RA, Kazmierczak BI. An indirect enzyme-linked immunosorbent assay for rapid and quantitative assessment of Type III virulence phenotypes of Pseudomonas aeruginosa isolates. Ann Clin Microbiol Antimicrob 2005; 4: 22.
4. Worgall S, Krause A, Qiu J, Joh J, Hackett NR, Crystal RG. Protective immunity to pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF. J Virol 2007; 81(24): 13801-8.
5. Perumal D, Lim CS, Chow VT, Sakharkar KR, Sakharkar MK. A combined computational-experimental analyses of selected metabolic enzymes in Pseudomonas species. Int J Biol Sci 2008; 4(5): 309-17.
6. Ramsey DM, Wozniak DJ. Understanding the control of Pseudomonas aeruginosa alginate synthesis and the prospects for management of chronic infection in cystic fibrosa. Mol Microbiol 2005;56(2): 309-22.
7. Stoodley P, Sauer K, Davies DG, Costerton JW. Biofilms as complex differentiated communities. Annu Rev Microbiol 2002; 56: 187-209.
8. Sugawara E, Nestorovich EM, Bezrukov SM, Nikaido H. Pseudomonas aeruginosa porin OprF exists in two different conformations. J Biol Chem 2006; 281(24): 16220-9.
9. O'May CY, Sanderson K, Roddam LF, Kirov SM, Reid DW. Ironbinding compounds impair Pseudomonas aeruginosa biofilm formation, especially under anaerobic conditions. J Med Microbiol 2009; 58(Pt 6): 765-73.
10. Hancock RE. The Pseudomonas aeruginosa outer membrane permeability barrier and how to overcome it. Antibiot Chemother (1971) 1985; 36: 95-102.
11. Ninane G, Harper PB. The in vitro activity of ceftazidime against a multi-resistant serotype 12 Pseudomonas aeruginosa. Infection 1983; 11 Suppl 1: S16-9.
12. Jamasbi J. Frequency and Distribution of Pseudomonas. J Bacteriol 2002; 184(13): 3614-22.
13. Al-Dujaili AH, Harris DM. Evaluation of commercially available antisera for serotyping of Pseudomonas aeruginosa. J Clin Pathol 1974; 27(7): 569-71.
14. van Belkum A, Tassios PT, Dijkshoorn L, Haeggman S, Cookson B, Fry NK, et al. Guidelines for the validation and application of typing methods for use in bacterial epidemiology. Clin Microbiol Infect 2007; 13 Suppl 3: 1-46.
15. Smith S, Ganiyu O, John R, Fowora M, Akinsinde K, Odeigah P. Antimicrobial resistance and molecular typing of pseudomonas aeruginosa isolated from surgical wounds in Lagos, Nigeria. Acta Med Iran 2012; 50(6): 433-8.
16. Adediran SG, Dauplaise DJ, Kasten KR, Tschöp J, Dattilo J, Goetzman HS, et al. Early infection during burn-induced inflammatory response results in increased mortality and p38-mediated neutrophil dysfunction. Am J Physiol Regul Integr Comp Physiol 2010; 299(3): R918-25.
17. Sardelić S Metalo-β -lactamases in carbapenem-resis tant clinical isolates of Pseudomonas aeruginosa [dissertation]. Zagreb: University of Zagreb Medical School Repository; 2010. (Croatian)
18. Gužvinec M, Butić I, Jelić M, Bukovski S, Lucić S, Tumbić-Andrašević A. Antimicrobial resistance in Pseudomonas aeruginosa. Infektol Glas 2012; 32(2): 71-80. (Croatian)
19. Bush K, Sykes RB. Characterization and epidemiology of β- lactamases. Philadelphia, PA: Elsevier Science Publishers BV; 1987.
20. Karakašević B. Manual of Standard Methods for microbiolo routine work. Beograd: Medicinska knjiga; 1967. (Serbian).
21. Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Suspectibility tests for bacteria That Grow Aerobicaly. Wayne: Clinical and Laboratory Standards Institute; 2012.
22. Al-Dujaili AH, Harris DM. Evaluation of commercially available antisera for serotyping of Pseudomonas aeruginosa. J Clin Pathol 1974; 27(7): 569-71.
23. Blanc DS, Petignat C, Janin B, Bille J, Francioli P. Frequency and molecular diversity of Pseudomonas aeruginosa upon admission and during hospitalization: a prospective epidemiologic study. Clin Microbiol Infect 1998; 4(5): 242-7.
24. Navon-Venezia S, Ben-Ami R, Carmeli Y. Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis 2005; 18(4): 306-13.
25. Q&A: What is Pseudomonas aeruginosa infection? [updated 2012 October 9]. Available from: http://www.bbc.co.uk/news/health-16645957
26. Centers for Disease Control and Prevention. Pseudomonas aeruginosa in Healthcare Settings. Available from: http://www.cdc.gov/hai/organisms/pseudomonas.htmlCDC
27. Marković Denić LJ. National study on the prevalence of hospital infections. VII National Conference "Introduction of the cultture of patients safety in the system of health protection of the Republic of Serbia" Belgrade; 2011 October 17; Belgrade: Ministry of Health, Republic of Serbia; Available from: http://www.minzdravlja.info/downloads/2011/Oktobar/Okto bar2011NacionalnaStudijaPrevalencijeBolnickihInfekcijaProfdrL jiljanaMarkovicDenic.pdf (Serbian)
28. Persson AE. Study of Pseudomonas aeruginosa and different wound dressing products. [thesis]. Göteborg, Sweden: Deparment of Chemical and Biological Engineering, Chalmers University of Technology; 2010.
29. Milic DJ, Zivic SS, Bogdanovic DC, Karanovic ND, Golubovic ZV. Risk factors related to the failure of venous leg ulcers to heal with compression treatment. J Vasc Surg 2009; 49(5): 1242-7.
30. Ranjan KP, Ranjan N, Bansal SK, Arora DR. Prevalence of Pseudomonas aeruginosa in post-operative wound infection in a referral hospital in Haryana, India. J Lab Physicians 2010; 2(2): 74-7. Retraction in: J Lab Physicians 2011; 3(2): 129.
31. Sivanmaliappan TS, Sevanan M. Antimicrobial Susceptibility Patterns of seudomonas aeruginosa from Diabetes Patients with Foot Ulcers. Int J Microbiol 2011; 2011: 605195.
32. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, et al. Antimicrobial-resistant pathogens associated with healthcare- associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013; 34(1): 1-14.
33. Salimi H, Yakhchali B, Owlia P, Rastegar Lari A. Molecular epidemiology and drug susceptibility of pseudomonas aeruginosa strains isolated from burn patients. Lab Med 2010; 41(9): 540-4.
34. Gjødsbøl K, Christensen JJ, Karlsmark T, Jørgensen B, Klein BM, Krogfelt KA. Multiple bacterial species reside in chronic wounds: a longitudinal study. Int Wound J 2006; 3(3): 225-31.
35. Yousefi S, Nahaei MR, Farajnia S, Aghazadeh M, Iversen A, Edquist P, et al. A multiresistant clone of Pseudomonas aeruginosa sequence type 773 spreading in a burn unit in Orumieh, Iran. APMIS 2013; 121(2): 146-52.
36. Higgins PG, Fluit AC, Milatovic D, Verhoef J, Schmitz FJ. Antimicrobial susceptibility of imipenem-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 2002; 50(2): 299-301.
37. Engler K, Mühlemann K, Garzoni C, Pfahler H, Geiser T, von Garnier C. Colonisation with Pseudomonas aeruginosa and antibiotic resistance patterns in COPD patients. Swiss Med Wkly 2012; 142: w13509.
38. Lepšanović Z, Libisch B, Tomanović B, Nonković Z, Balogh B, Fuzi M. Characterisation of the first VIM metallolactamasae-producing Pseudmonas aeruginosa clinical isolates in Serbia. Acta Microbiol Immunol Hung 2008; 55(4): 447-54.
39. Jovcic B, Vasiljevic Z, Djukic S, Topisirovic Š, Kojic M. Emergence of VIM-2 metallo-β-lactamase-producing Pseudomonas aeruginosa isolates in a paediatric hospital in Serbia. J Med Microbiol 2011; 60(Pt 6): 868-9.
40. Bosnjak Z, Bedenić B, Mazzariol A, Jarza-Davila N, Suto S, Kalenić S. VIM-2 beta-lactamase in Pseudomonas aeruginosa isolates from Zagreb, Croatia. Scand J Infect Dis 2010; 42(3): 193-7.
41. Gutiérrez O, Juan C, Cercenado E, Navarro F, Bouza E, Coll P, et al. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. Antimicrob Agents Chemother 2007; 51(12): 4329-35.
42. Giakkoupi P, Petrikkos G, Tzouvelekis LS, Tsonas S, Legakis NJ, Vatopoulos AC. Spread of integron-associated VIM-type metallo beta-lactamase genes among imipenem-nonsusceptible Pseudomonas aeruginosa strains in Greek hospitals. J Clin Microbiol 2003; 41(2): 822-5.
43. Pournaras S, Maniati M, Petinaki E, Tzouvelekis LS, Tsakris A, Legakis NJ, et al. Hospital outbreak of multiple clones of Pseudomonas aeruginosa carrying the unrelated metallo-beta-lactamase gene variants blaVIM-2 and blaVIM-4. J Antimicrob Chemother 2003; 51(6): 1409-14.
44. Pitout JD, Chow BL, Gregson DB, Laupland KB, Elsayed S, Church DL. Molecular epidemiology of metallo-beta-lactamaseproducing Pseudomonas aeruginosa in the Calgary Health Region: emergence of VIM-2-producing isolates. J Clin Microbiol 2007; 45(2): 294-8.
45. Tomanović B, Jokovic B, Tatić M, Mirović V, Nanusević O. Serotyping and pyocin typing of Pseudomonas aeruginosa in a study of intrahospital infections. Vojnosanit Pregl 1991; 48(1): 31-3. (Serbian)
46. Müller-Premru M, Gubina M. Serotype, antimicrobial susceptibility and clone distribution of Pseudomonas aeruginosa in a university hospital. Zentralbl Bakteriol 2000; 289(8): 857-67.